CPT 81427: Reanalysis of Full Genomic Sequence
Commercial payers pay $2106 on average nationally for this procedure.
CPT code 81427 describes a clinical laboratory service in which a lab analyst performs a reevaluation of an existing full genomic sequence analysis using new clinical information or other data not available at the time of the initial interpretation; this service is a reanalysis of genomic sequencing typically provided as a laboratory-based genetic diagnostic consult and is performed in a clinical laboratory or molecular diagnostics setting for an established patient's prior whole genome or full genomic sequence report.
Customize your policy alerts
Sign up for cpt 81427 policy alerts
Get alerted when payer policies referencing 81427 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial market rates for CPT 81427 cluster around BUCA’s average commercial benchmark of $2,105.90, offering a useful midpoint for national comparison. Blue Cross Blue Shield shows a high mean and wide upper-end values, with a median of $2,282.10 that sits slightly above BUCA’s average, while Cigna’s median of $2,094.50 closely aligns with BUCA. Aetna’s mean of $217.50 is far below other payers and its P90 at $806.40 indicates most commercial payments are very low compared with the other carriers.
Dispersion (P75 minus P25) highlights where rates are most and least tightly clustered: Blue Cross Blue Shield’s dispersion is $936.10 (P75 $2,688.80 minus P25 $1,752.70), Cigna’s dispersion is $1,888.70 (P75 $3,087.80 minus P25 $1,199.10), UnitedHealth Group’s dispersion is $1,356.90 (P75 $2,337.70 minus P25 $981.80), and BUCA’s interquartile span is $998.40 (P75 $2,311.50 minus P25 $1,313.10). Cigna is the widest by this measure and Blue Cross Blue Shield is the tightest.